Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27)

Nature of Filing / Announcement: Regulatory Filing under SEBI Listing Regulations 30, 33, 51, and 52

Date of Board Meeting / Approval: October 26, 2026 (01:45 PM IST to 02:45 PM IST)

Audit Opinion: Unmodified conclusion with Emphasis of Matter

Auditor's Comment: Emphasis of Matter regarding uncertainty of income tax proceedings initiated by Income Tax Department pursuant to search conducted in an earlier year under Section 132 of Income Tax Act, 1961. Appeal is currently pending with appellate tax authorities.

Key Financial Highlights [₹ Crores]

Standalone Results:

Revenue from Operations: Q2 FY27: ₹3,145.22 (YoY: +19.3% from ₹2,636.95 in Q2 FY26); H1 FY27: ₹6,109.27 (YoY: +17.3% from ₹5,206.68 in H1 FY26)

Total Income: Q2 FY27: ₹3,204.05; H1 FY27: ₹6,202.06

Net Profit: Q2 FY27: ₹581.95 (YoY: +26.6% from ₹459.80); H1 FY27: ₹1,140.44 (YoY: +30.3% from ₹875.07)

EPS: Basic EPS Q2 FY27: ₹14.09; H1 FY27: ₹27.62 (Not annualized)

Other Equity: As of September 30, 2026: ₹17,522.98 (vs. ₹16,355.66 as of March 31, 2026)

Cash and Cash Equivalents: As of September 30, 2026: ₹828.56 (vs. ₹87.66 as of March 31, 2026)

Debt:

  • Current Borrowings: ₹1,840.68
  • Non-current Borrowings: ₹2,649.41
  • Total Debt: ₹4,490.09

Consolidated Results:

Revenue from Operations: Q2 FY27: ₹4,337.86; H1 FY27: ₹8,368.45

Total Income: Q2 FY27: ₹4,432.71; H1 FY27: ₹8,508.30

Net Profit: Q2 FY27: ₹716.12; H1 FY27: ₹1,290.21

Attribution:

  • Equity holders of parent: Q2 FY27: ₹711.48; H1 FY27: ₹1,279.54
  • Non-controlling interests: Q2 FY27: ₹4.64; H1 FY27: ₹10.67

EPS: Basic EPS Q2 FY27: ₹17.23; H1 FY27: ₹30.99 (Not annualized)

Other Equity: As of September 30, 2026: ₹17,540.92 (vs. ₹16,259.06 as of March 31, 2026)

Cash and Cash Equivalents: As of September 30, 2026: ₹1,113.82 (vs. ₹391.69 as of March 31, 2026)

Segment-wise Performance: The Company has only one reportable segment 'Pharmaceuticals' as per Ind AS 108.

Corporate Actions:

Dividend: Not declared in this meeting.

Amalgamation Schemes:

1. Scheme 1: Approved amalgamation of wholly-owned subsidiaries Prolijune Lifesciences Private Limited (Transferor Company 1) and Pavi Buildwell Private Limited (Transferor Company 2) with and into Mankind Pharma Limited (Transferee Company). Appointed Date: April 1, 2027. Exempt from Stock Exchange NOC requirement under Regulation 37(6) of Listing Regulations. Subject to NCLT, shareholder, creditor, and other approvals.

2. Scheme 2: Noted amalgamation of Upakarma Ayurveda Private Limited (Transferor Company, wholly-owned subsidiary of MCPPL) with and into Mankind Consumer Products Private Limited (Transferee Company, wholly-owned subsidiary of Mankind Pharma). Subject to statutory and regulatory approvals.

Other Significant Information:

Investment in Subsidiaries: During H1 FY27, invested in various subsidiaries including Mankind Pharma LLC (₹17.11 crores), Mankind Pharma (Netherlands) B.V. (₹0.22 crores), Mankind Life Sciences Private Limited (₹8.00 crores), Mankind Petcare Private Limited (₹10.00 crores), and Mankind Medicare Private Limited (₹140.00 crores).

ESOP: Granted 93,750 stock options and allotted 216,762 equity shares under Mankind Employees Stock Option Plan 2022 to eligible employees of Company and subsidiaries during H1 FY27.

Business Combination: Acquired Branded Generic Business (Women's Health Portfolio) of Bharat Serums and Vaccines Limited (wholly-owned subsidiary) for ₹797 crores effective November 1, 2025. Accounted as common control business combination under Ind AS 103.

Exceptional Items: ₹106.24 crores in FY26 comprised of incremental impact of Labour Code changes (₹87.22 crores for gratuity and long-term compensated absences) and stamp duty paid for IP assignment (₹19.02 crores).

Subsidiary Sale: Approved sale of entire stake in Broadway Hospitality Services Private Limited (wholly-owned subsidiary) to AKRK Projects LLP and its Partners. Share Purchase Agreement executed on July 27, 2025.